Tenpoint Therapeutics
London, Capital Region of Denmark, United Kingdom · Biotechnology, Health Care, Therapeutics · 25 employees
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells
Funding history
- Series B — $235.0M — Jan 2026
- Series A — $70.0M — Jul 2023
Recent signals
- Apr 24, 2026: Tenpoint Therapeutics Appoints Stephen Lane as Chief Medical Officer
- Apr 07, 2026: Tenpoint Therapeutics Appoints Stephen S. Lane as Chief Medical Officer
- Jan 29, 2026: Raised $235.0M in Series B
- Mar 12, 2025: Tenpoint Appoints Carol Kearney as Chief Commercial Officer for the Potential U.S. Launch of BRIMOCHOL™ PF
- Jan 09, 2025: Launched Tenpoint Therapeutics, Inc. announces positive topline data from BRIO-II study for BRIMOCHOL™ PF to treat presbyopia.
- Jul 12, 2023: Raised $70.0M in Series A
See plans & pricing → Track Tenpoint Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.